CRANBURY, N.J., April 20, 2021 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN), a specialized
biopharmaceutical company developing first-in-class medicines based
on molecules that modulate the activity of the melanocortin peptide
receptor system, today announced two presentations of the Company's
melanocortin platform, including PL9643 in dry eye disease, at the
Association for Research in Vision and Ophthalmology (ARVO) 2021
Annual Meeting, being held virtually May
1-7, 2021.
The presentations highlight the positive clinical data from the
Phase 2 clinical study in dry eye disease patients, and the
possible utility of melanocortins in the treatment of inflammation
and, specifically, ocular inflammation.
"Palatin is excited to present two examples of the significant
utility of melanocortins in the treatment for inflammatory
conditions. The eye, as well as the gut and kidney, offer a
unique environment where melanocortin agonism promotes resolution
of inflammation," said Carl Spana, Ph.D., President and CEO of
Palatin. "ARVO is the premier global eye and vision forum. We are
pleased to showcase Palatin's expertise with melanocortin peptides
and how they may provide a safe, well-tolerated, and effective
treatment path for inflammatory conditions in the eye."
The presentation details:
Date:
|
May 1,
2021
|
Time:
|
3:15 pm to 4:45 pm
Eastern Time
|
Session
Title:
|
Dry eye clinical
treatments
|
Format:
|
Podium
Presentation
|
Presenter:
|
Kenneth Kenyon, MD,
treating ophthalmologist and primary investigator
|
Title:
|
"Efficacy
and Safety of the Melanocortin Agonist PL9643 in a Phase 2 Study of
Subjects with Dry Eye Disease"
|
|
|
Date:
|
May 6,
2021
|
Time:
|
11:15am – 1:00pm
Eastern Time
|
Session
Title:
|
Stem cells/gene
therapy/transplantation/laser/local therapy
|
Format:
|
Poster
Presentation
|
Presenter:
|
John Dodd, PhD,
Senior Vice President of Preclinical Research
|
Title:
|
"Protective
Effects of 2 Melanocortin Agonists Delivered by Intravitreal
Injection in Mouse Models of Retinopathy"
|
Both presentations will be available on the Palatin website,
www.palatin.com, after the ARVO annual meeting ends on May 7, 2021.
About Melanocortins and Inflammation
The melanocortin receptor ("MCr") system has effects on food
intake, metabolism, sexual function, inflammation, and immune
system responses. There are five melanocortin receptors, MC1r
through MC5r. Modulation of these receptors, through use of
receptor-specific agonists, which activate receptor function, or
receptor-specific antagonists, which block receptor function, can
have significant pharmacological effects.
Many tissues and immune cells located in the eye express
melanocortin receptors, empowering our opportunity to directly
activate natural pathways to resolve disease inflammation.
About Dry Eye Disease
Dry eye disease is a common inflammatory disease that, left
untreated, can become extremely painful and lead to permanent
damage to the cornea and vision. Dry eye disease affects the cornea
and conjunctiva of the eye resulting in irritation, redness, pain,
and blurred vision. It is estimated to affect over 20 million
people in the United States.
The disease is characterized by insufficient moisture and
lubrication in the anterior surface of the eye, leading to dryness,
inflammation, pain, discomfort, irritation, diminished quality of
life, and in severe cases, permanent vision impairment. Existing
therapy for dry eye disease is generally regarded as inadequate by
many physicians and patients, and often requires weeks or months to
demonstrate activity.
About ARVO
ARVO is the largest and one of the most respected eye and vision
research organizations in the world and its members include almost
11,000 researchers from over 75 countries. The members of
ARVO cover multiple specialties and consist of both clinical and
basic researchers. ARVO advances research worldwide about the
visual system and preventing, treating, and curing its
disorders.
About Palatin
Palatin researches, develops, and designs novel peptide, peptide
mimetic, and small molecule agonist compounds with high selectivity
for specific melanocortin receptors. Our current focus is on the
design and development of proprietary melanocortin receptor
agonists for inflammation and autoimmune conditions, with a focus
on ocular diseases. Our therapeutics work by activating endogenous
melanocortin pathways to resolve damaging inflammation and allow
affected tissues time to heal. Research has shown melanocortin
agonists can prevent and reverse inflammation in disease models,
including in the eyes and intestine - two of our targeted areas.
For additional information regarding Palatin, please visit
Palatin's website at www.palatin.com.
Forward-looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin , such as
statements about clinical trial results, potential actions by
regulatory agencies including the FDA, regulatory plans,
development programs, proposed indications for product candidates,
market potential for product candidates, and potential adverse
impacts due to the global COVID-19 pandemic such as delays in
regulatory review, manufacturing and supply chain interruptions,
adverse effects on healthcare systems and disruption of the global
economy, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and as that term is defined in the
Private Securities Litigation Reform Act of 1995. Palatin intends
that such forward-looking statements be subject to the safe harbors
created thereby. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that could cause
Palatin's actual results to be materially different from its
historical results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and other regulatory and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating for events that
occur after the date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/palatin-announces-two-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting-301272303.html
SOURCE Palatin Technologies, Inc.